Comparison of goserelin and leuprolide in combined androgen blockade (CAB) for advanced prostate cancer.

被引：0
|
作者：
Sarosdy, MF
Schellhammer, PF
Block, NL
Soloway, MS
Venner, PM
Patterson, AL
Sharifi, R
Vogelzang, NJ
Chodak, GW
Klein, EA
Schellenger, JJ
Kolvenbag, GJCM
机构：
来源：
JOURNAL OF UROLOGY | 1998年 / 159卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
1300
引用
收藏
页码：338 / 338
页数：1
相关论文
共 50 条
  • [21] Goserelin versus leuprolide in the chemical castration of patients with prostate cancer
    Silva, Elcio Dias
    Ferreira, Ubirajara
    Matheus, Wagner
    Faria, Eliney F.
    Silva, Gustavo D.
    Saito, Minori
    de Souza, Auro A. S.
    Laranjo, Azuil, Jr.
    Clark, Otavio
    Magna, Luis Alberto
    Castilho, Lisias Nogueira
    Reis, Leonardo Oliveira
    INTERNATIONAL UROLOGY AND NEPHROLOGY, 2012, 44 (04) : 1039 - 1044
  • [22] Goserelin versus leuprolide in the chemical castration of patients with prostate cancer
    Élcio Dias Silva
    Ubirajara Ferreira
    Wagner Matheus
    Eliney F. Faria
    Gustavo D. Silva
    Minori Saito
    Auro A. S. de Souza
    Azuil Laranjo
    Otavio Clark
    Luis Alberto Magna
    Lísias Nogueira Castilho
    Leonardo Oliveira Reis
    International Urology and Nephrology, 2012, 44 : 1039 - 1044
  • [23] 10.8 mg goserelin every 13 weeks for advanced prostate cancer.
    Sarosdy, MF
    Schellhammer, PF
    Soloway, MS
    Vogelzang, NJ
    Crawford, ED
    Presti, J
    Kelley, P
    Mitchell, P
    Porter, L
    BRITISH JOURNAL OF CANCER, 1998, 78 : 38 - 38
  • [24] Combined androgen blockade is the treatment of choice for patients with advanced prostate cancer: The argument against
    Fitzpatrick, JM
    EUROPEAN UROLOGY, 1996, 29 : 37 - 39
  • [25] Combined androgen blockade is underused in advanced prostate cancer: Findings from an international survey
    Castro-Diaz, D.
    Gillatt, D.
    Payne, H.
    Akaza, H.
    EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 86 - 86
  • [26] Combined androgen blockade for the treatment of metastatic cancer of the prostate
    Schellhammer, PF
    UROLOGY, 1996, 47 (05) : 622 - 628
  • [27] Sequential androgen blockade in patients with advanced prostate cancer
    Trachtenberg, J
    Fleshner, NE
    MOLECULAR UROLOGY, 1998, 2 (03) : 201 - 205
  • [28] Role of maximum androgen blockade in advanced prostate cancer
    Ayyathurai, Rajinikanth
    Santos, Rosely De Los
    Manoharan, Murugesan
    INDIAN JOURNAL OF UROLOGY, 2009, 25 (01) : 47 - 51
  • [29] CHLORMADINONE ACETATE WITHDRAWAL SYNDROME UNDER COMBINED ANDROGEN BLOCKADE FOR ADVANCED PROSTATE-CANCER
    SEKIDO, N
    KAWAI, K
    AKAZA, H
    KOISO, K
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 1995, 25 (04) : 164 - 167
  • [30] Effects of combined androgen blockade on bone metabolism and density in men with locally advanced prostate cancer
    Tan M.O.
    Yilmaz C.
    Uygur M.C.
    Duyur B.
    Erol D.
    International Urology and Nephrology, 2002, 34 (1) : 75 - 79
12345